Soligenix (DB:DOA) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

DOA Panoramica delle azioni

A late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States.

Informazioni sull'azienda

DOA analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 75.85% all'anno

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 1.5% all'anno per i prossimi 3 anni

Non ha una capitalizzazione di mercato significativa ( €9M )

Realizza un fatturato inferiore a 1 milione di dollari ( $949K )

Patrimonio netto negativo

+ 3 più rischi

Soligenix, Inc. Concorrenti

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€29.5m

Epigenomics

DB:ECX

€568.8k

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Soligenix
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$5.85
Massimo di 52 settimane	US$14.11
Minimo di 52 settimane	US$5.58
Beta	1.74
1Variazione di 1 mese	0%
Variazione a 3 mesi	-5.11%
Variazione di 1 anno	-10.53%
3Variazione a 3 anni	-73.29%
Variazione a 5 anni	-71.94%
Variazione dall'IPO	-77.87%

Notizie e aggiornamenti recenti

Recent updates

Rendimenti per gli azionisti

	DOA	DE Biotechs	DE Mercato
7D	0%	1.0%	1.5%
1Y	-10.5%	-15.4%	12.6%

Ritorno vs Industria: DOA ha superato il German Biotechs che ha restituito -22 % nell'ultimo anno.

Rendimento vs Mercato: DOA ha avuto una performance inferiore al mercato German che ha registrato un rendimento 4.7 % nell'ultimo anno.

Volatilità dei prezzi

Is DOA's price volatile compared to industry and market?
DOA volatility
DOA Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	11.7%
10% least volatile stocks in DE Market	2.4%

Prezzo delle azioni stabile: DOA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: Dati insufficienti per determinare la variazione della volatilità di DOA nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1987	14	Christopher Schaber	www.soligenix.com

Soligenix, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Soligenix con la sua capitalizzazione di mercato?
DOA statistiche fondamentali
Capitalizzazione di mercato	€7.89m
Guadagni(TTM)	-€12.59m
Ricavi(TTM)	€865.50k

9.1x

Rapporto P/S

-0.6x

Rapporto P/E

DOA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
DOA Conto economico (TTM)
Ricavi	US$948.91k
Costo del fatturato	US$550.82k
Profitto lordo	US$398.09k
Altre spese	US$14.20m
Guadagni	-US$13.80m

Ultimi guadagni dichiarati

Dec 31, 2022

Prossima data di guadagno

n/a

Utile per azione (EPS)	-1.45
Margine lordo	41.95%
Margine di profitto netto	-1,454.12%
Rapporto debito/patrimonio netto	-400.6%

Come si è comportato DOA nel lungo periodo?

Vedi performance storica e confronto

DOA Panoramica delle azioni

Premi

Analisi del rischio

Soligenix, Inc. Concorrenti

XTRA:CNW

€6.5m

XTRA:MDG1

€29.5m

DB:ECX

€568.8k

BST:BPXA

€772.4k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Recent updates

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Publication Demonstrating Positive Correlates of Protection with Rivax® in Non-Human Primate Survival After Ricin Challenge

Soligenix, Inc. Initiates Phase 2 Clinical Trial of SGX302 (Synthetic Hypericin) for the Treatment of Mild-To-Moderate Psoriasis

Soligenix Announces Submission of New Drug Application to the FDA for Hybryte™ in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Receives Non Compliance Notice from Nasdaq

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.077 loss per share (vs US$0.088 loss in 3Q 2021)

Soligenix, Inc. Announces U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Second quarter 2022 earnings released: US$0.055 loss per share (vs US$0.047 loss in 2Q 2021)

Soligenix, Inc., Annual General Meeting, Sep 22, 2022

Soligenix, Inc. Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in Treatment of Psoriasis

Soligenix Announces Successful Protection Using A Bivalent Thermostabilized Filovirus Vaccine

Soligenix Receives US Patent Allowance for Its Thermostabilized Vaccine Platform

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.064 loss in 1Q 2021)

Insufficient new directors

No longer forecast to breakeven

Full year 2021 earnings released: US$0.31 loss per share (vs US$0.64 loss in FY 2020)

Soligenix, Inc. Demonstrates Positive Anti-Tumor Efficacy in Multiple Nonclinical Animal Studies

Forecast to breakeven in 2024

Third quarter 2021 earnings released: US$0.088 loss per share (vs US$0.061 loss in 3Q 2020)

Insufficient new directors

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Soligenix, Inc. Riepilogo dei fondamenti

9.1x

-0.6x

Guadagni e ricavi